Radiation Oncology

Radiation therapy uses high-energy radiation to damage cancer cells' DNA and destroy their ability to divide and grow. It is delivered using linear accelerators, proton accelerators, metered cobalt-60 exposure, or brachytherapy where radioactive seeds are placed inside the patient on a temporary or permanent basis to kill cancer or relieve pain. The main radiation oncology society and annual conference is the American Society of Radiation Oncology (ASTRO).

ASTRO 2018: Radiation therapy outcomes better for black prostate cancer patients than white patients

Black men with prostate cancer may have “comparatively higher” cure rates than white men when treated with radiation therapy, according to study results presented Oct. 22 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

October 22, 2018

ASTRO 2018: Side effects similar for women receiving weekly breast radiation therapy, daily treatments

Among women receiving radiation therapy to treat early-stage breast cancer, receiving larger individual doses was not associated with a significant increase in long-term side effects, according to a 10-year study presented Oct. 21 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

October 22, 2018

At ASTRO, Siemens Healthineers unveil RT Pro Edition for Biograph Vision for PET/CT radiation therapy planning

RT package of latest PET/CT scanner offers comprehensive therapy planning solution.

October 22, 2018

Fujifilm announces entry Into U.S. computed tomography market with unveiling of FCT Embrace at ASTRO 2018

World's first 85cm 64 and 128 slice wide bore CT unit for oncology

October 22, 2018
a patient talks with her doctor, both are women of color

ASTRO 2018: Radiation therapy makes low recurrence rates among some breast cancer patients even lower

Radiation therapy can lower the chance of cancer recurrence in patients with low-risk breast cancer following breast conservation surgery, according to data presented Oct. 21 at the American Society for Radiation Oncology (ASTRO) Annual Meeting in San Antonio, Texas.

October 22, 2018

FUJIFILM ANNOUNCES ENTRY INTO U.S. COMPUTED TOMOGRAPHY MARKET WITH UNVEILING OF FCT EMBRACE AT ASTRO 2018

STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

October 22, 2018

ASTRO, industry leaders issue new radiation treatment guidelines for early-stage prostate cancer

Prominent medical societies have issued new clinical guidelines, Thursday, Oct. 11, recommending physicians use external beam radiation therapy (EBRT) to treat men with early-stage prostate cancer.

October 12, 2018